Quo vadis, biotech? (Part 1).
The recent increase in the capitalization value of the biotechnology industry appears to be sustainable. The phenomenon is interpreted as an acknowledgement by the markets that this industry has become the main source of innovation for the pharmaceutical industry. In addition, biotechnology is beginning to impact on other industries. However, from a methodological and strategic point of view, the biotechnology industry is still too fragmented. Consolidation along the lines of value generation in drug research and development, however, will occur. Over the next 5 to 10 years, the biotechnology industry will remain the fastest growing industry in the health care arena.
Drews
J
International Biomedicine Management Partners, Basel, Switzerland